Lupine Receives USFDA Presumptive Approval for ANDA Drospirenone Tablets | Tech Reddy
[ad_1] Business standard Lupine today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Drospirenone Tablets, 4 mg, to market the generic equivalent of Exeltis, Slind Tablets, 4 … Read more